Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 5;17(7):1235.
doi: 10.3390/cancers17071235.

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Benjamin Derman  1 , Carlyn Tan  2 , Ian Steinfield  3 , Florence R Wilson  4 , Dee Lin  5 , Bingcao Wu  5 , Mariana Fernandez  6 , Jessica Fowler  5 , Agne Paner-Straseviciute  5 , Nina Kim  5 , Margaret Doyle  7 , Alexander Marshall  8 , Jessica Cheadle  5 , Sam Keeping  4 , Jane Jijun Liu  9
Affiliations
Review

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Benjamin Derman et al. Cancers (Basel). .

Abstract

Background: Teclistamab (TEC) is the first B-cell maturation antigen-directed bispecific antibody approved in 2022 by the European Medicines Agency and Food and Drug Administration for triple-class exposed relapsed/refractory multiple myeloma (RRMM). Objectives: As TEC is increasingly used in real-world (RW) settings, this study seeks to gather existing RW evidence on effectiveness, safety, healthcare resource utilization, and clinical practices associated with TEC. Methods: A systematic literature review was performed to identify RW observational studies of TEC-treated adults with RRMM from 2023 to June 2024. Results: Sixty-one records representing 41 unique studies were included; sample sizes ranged from 8 to 572 patients. Where reported, median follow-up ranged from 2.3 to 33.6 months, and >65% of the patients would have been ineligible for the pivotal trial of TEC (MajesTEC-1) in all but one study. In eight studies with ≥50 patients and ≥3 months follow-up, overall response rates were 59-66% and cytokine release syndrome (CRS) rates were 18-64%. Tocilizumab use for CRS management was reported in 14 studies, with two indicating CRS rates of 13% and 26% when used prophylactically. Survival and infection outcomes showed wide variability due to short follow-up in most studies. Conclusions: Overall, early RW effectiveness and safety outcomes of TEC were comparable to findings from MajesTEC-1.

Keywords: B-cell maturation antigen; bispecific antibodies; cytokine release syndrome; immune effector cell-associated neurotoxicity syndrome; real-world evidence; relapsed–refractory multiple myeloma; systematic literature review; teclistamab.

PubMed Disclaimer

Conflict of interest statement

B. Derman is an employee of UChicago Medicine and declares consulting services for Janssen Scientific Affairs, Cota Healthcare, Guidepoint Global, Gerson Lehrman Group, Precision AQ, Sanofi, and Canopy, as well as honoraria from OncLive/MJH Life Sciences, Plexus, and Multiple Myeloma Research Foundation and research funding from GlaxoSmithKline and Amgen. C. Tan is an employee of the Memorial Sloan Kettering Cancer Center and declares consulting services for Janssen Medical Affairs and Sanofi, honoraria from MJH Life Sciences, and may hold stock and other ownership interests in Johnson & Johnson/Janssen, Moderna Therapeutics, ImmunityBio, Nektar, and Pfizer and research funding from Janssen and Takeda. I. Steinfield, F.R. Wilson, and S. Keeping are employees of Precision AQ. D. Lin, B. Wu, M. Fernandez, J. Fowler, A. Paner-Straseviciute, N. Kim, M. Doyle, A. Marshall, and J. Cheadle are employees of Johnson & Johnson Innovative Medicine and may hold stock or stock options of Johnson & Johnson. J.J. Liu is an employee of the Illinois Cancer Care.

Figures

Figure 1
Figure 1
PRISMA flow diagram of included studies. Abbreviations: ASCO, American Society of Clinical Oncology; ASH, American Society for Hematology; EHA, European Hematology Association; HOPA, Hematology/Oncology Pharmacy Association; IMS, International Myeloma Society; LL&M, Lymphoma, Leukemia & Myeloma Congress; ONS, Oncology Nursing Society; SOHO, Society of Hematologic Oncology.
See this image and copyright information in PMC

References

    1. National Cancer Institute SEER Cancer Stat Facts: Myeloma. [(accessed on 2 August 2024)]; Available online: https://seer.cancer.gov/statfacts/html/mulmy.html.
    1. Padala S.A., Barsouk A., Barsouk A., Rawla P., Vakiti A., Kolhe R., Kota V., Ajebo G.H. Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci. 2021;9:3. doi: 10.3390/medsci9010003. - DOI - PMC - PubMed
    1. Hari P., Romanus D., Palumbo A., Luptakova K., Rifkin R.M., Tran L.M., Raju A., Farrelly E., Noga S.J., Blazer M., et al. Prolonged Duration of Therapy Is Associated with Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. Clin. Lymphoma Myeloma Leuk. 2018;18:152–160. doi: 10.1016/j.clml.2017.12.012. - DOI - PubMed
    1. Jagannath S., Joseph N., He J., Crivera C., Fu A.Z., Garrett A., Shah N. Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States. Oncol. Ther. 2022;10:411–420. doi: 10.1007/s40487-022-00198-0. - DOI - PMC - PubMed
    1. Bazarbachi A.H., Al Hamed R., Malard F., Harousseau J.L., Mohty M. Relapsed refractory multiple myeloma: A comprehensive overview. Leukemia. 2019;33:2343–2357. doi: 10.1038/s41375-019-0561-2. - DOI - PubMed

LinkOut - more resources